CBT
Cabot Corporation
Chemicals - Specialty
Market Cap$4.24B
5Y Perf.+127.5%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
CBT vs TROX vs CC vs KRO
Revenue, margins, valuation, and 5-year total return — side by side.
TROX
Tronox Holdings plc
Chemicals
Market Cap$1.34B
5Y Perf.+26.7%
CC
The Chemours Company
Chemicals - Specialty
Market Cap$3.36B
5Y Perf.+70.9%
KRO
Kronos Worldwide, Inc.
Chemicals - Specialty
Market Cap$811M
5Y Perf.-27.8%
CBT vs TROX vs CC vs KRO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | CBT | TROX | CC | KRO |
|---|---|---|---|---|
| Industry | Chemicals - Specialty | Chemicals | Chemicals - Specialty | Chemicals - Specialty |
| Market Cap | $4.24B | $1.34B | $3.36B | $811M |
| Revenue (TTM) | $3.58B | $2.92B | $5.82B | $1.88B |
| Net Income (TTM) | $285M | $-359M | $-411M | $-134M |
| Gross Margin | 24.8% | 5.8% | 15.1% | 10.1% |
| Operating Margin | 15.7% | -4.8% | -0.8% | -3.1% |
| Forward P/E | 13.0x | — | 15.5x | — |
| Total Debt | $1.22B | $3.59B | $4.58B | $577M |
| Cash & Equiv. | $258M | $211M | $672M | $37M |
CBT vs TROX vs CC vs KRO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
CBT
TROX
CC
KRO
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Cabot Corporation (CBT) | 100 | 227.5 | +127.5% |
| Tronox Holdings plc (TROX) | 100 | 126.7 | +26.7% |
| The Chemours Company (CC) | 100 | 170.9 | +70.9% |
| Kronos Worldwide, I… (KRO) | 100 | 72.2 | -27.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CBT vs TROX vs CC vs KRO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CBT leads in 5 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. The Chemours Company is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
CBT
Cabot Corporation
The Income Pick
CBT carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- Dividend streak 4 yrs, beta 0.78, yield 2.2%
- Lower volatility, beta 0.78, Low D/E 71.3%, current ratio 1.61x
- Better valuation composite
- 8.0% margin vs TROX's -12.3%
Best for: income & stability and sleep-well-at-night
TROX
Tronox Holdings plc
The Income Angle
TROX plays a supporting role in this comparison — it may shine differently against other peers.
Best for: basic materials exposure
CC
The Chemours Company
The Long-Run Compounder
CC is the #2 pick in this set and the best alternative if long-term compounding is your priority.
- 219.7% 10Y total return vs KRO's 129.0%
- 0.4% revenue growth vs CBT's -7.0%
- +108.8% vs KRO's -1.2%
Best for: long-term compounding
KRO
Kronos Worldwide, Inc.
The Growth Play
KRO is the clearest fit if your priority is growth exposure and defensive.
- Rev growth -1.5%, EPS growth -228.0%, 3Y rev CAGR -1.2%
- Beta 1.57, yield 2.8%, current ratio 2.70x
Best for: growth exposure and defensive
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | CC | 0.4% revenue growth vs CBT's -7.0% |
| Value | CBT | Better valuation composite |
| Quality / Margins | CBT | 8.0% margin vs TROX's -12.3% |
| Stability / Safety | CBT | Beta 0.78 vs TROX's 2.37, lower leverage |
| Dividends | CBT | 2.2% yield, 4-year raise streak, vs TROX's 3.6% |
| Momentum (1Y) | CC | +108.8% vs KRO's -1.2% |
| Efficiency (ROA) | CBT | 7.4% ROA vs KRO's -9.4%, ROIC 17.4% vs -1.9% |
CBT vs TROX vs CC vs KRO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
FY 2025
FY 2014
CBT vs TROX vs CC vs KRO — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLCBTLAGGINGKRO
Who Leads Where
CBT leads in 5 of 6 categories
TROX leads 0 • CC leads 0 • KRO leads 0 • 1 tied
Explore the data ↓KROKronos Worldwide, Inc.
0leads
CCThe Chemours Company
0leads
TROXTronox Holdings plc
0leads
CBTCabot Corporation
5leads
6 Total Categories
CATEGORYLEADERvs TROXvs CCMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
CBT4/6
Valuation MetricsMultiples, price ratios, and targets
CBT3/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
CBT7/9
Total Returns1Y, 3Y, 5Y total returns with dividends
CBT3/6
Risk & VolatilityBeta, volatility, and downside exposure
CBT2/2
Analyst OutlookRatings, price targets, and dividends
Tied
—
Income & Cash Flow (Last 12 Months)
CBT leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
CC is the larger business by revenue, generating $5.8B annually — 3.1x KRO's $1.9B. CBT is the more profitable business, keeping 8.0% of every revenue dollar as net income compared to TROX's -12.3%. On growth, KRO holds the edge at +4.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | CBTCabot Corporation | TROXTronox Holdings p… | CCThe Chemours Comp… | KROKronos Worldwide,… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $3.6B | $2.9B | $5.8B | $1.9B |
| EBITDAEarnings before interest/tax | $731M | $166M | -$132M | -$9M |
| Net IncomeAfter-tax profit | $285M | -$359M | -$411M | -$134M |
| Free Cash FlowCash after capex | $459M | -$139M | $198M | $35M |
| Gross MarginGross profit ÷ Revenue | +24.8% | +5.8% | +15.1% | +10.1% |
| Operating MarginEBIT ÷ Revenue | +15.7% | -4.8% | -0.8% | -3.1% |
| Net MarginNet income ÷ Revenue | +8.0% | -12.3% | -7.1% | -7.1% |
| FCF MarginFCF ÷ Revenue | +12.8% | -4.8% | +3.4% | +1.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | -3.4% | +3.0% | +1.0% | +4.1% |
| EPS Growth (YoY)Latest quarter vs prior year | -23.1% | +7.1% | -6.1% | -126.1% |
CBT leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
CBT leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, CBT's 6.7x EV/EBITDA is more attractive than KRO's 40.7x.
| Metric | CBTCabot Corporation | TROXTronox Holdings p… | CCThe Chemours Comp… | KROKronos Worldwide,… |
|---|---|---|---|---|
| Market CapShares × price | $4.2B | $1.3B | $3.4B | $811M |
| Enterprise ValueMkt cap + debt − cash | $5.2B | $4.7B | $7.3B | $1.4B |
| Trailing P/EPrice ÷ TTM EPS | 13.50x | -2.83x | -8.75x | -7.34x |
| Forward P/EPrice ÷ next-FY EPS est. | 13.04x | — | 15.55x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 6.71x | 16.80x | 21.72x | 40.71x |
| Price / SalesMarket cap ÷ Revenue | 1.14x | 0.46x | 0.58x | 0.44x |
| Price / BookPrice ÷ Book value/share | 2.58x | 0.92x | 13.44x | 1.08x |
| Price / FCFMarket cap ÷ FCF | 10.86x | — | 65.93x | — |
CBT leads this category, winning 3 of 6 comparable metrics.
Profitability & Efficiency
CBT leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
CBT delivers a 16.8% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-163 for CC. CBT carries lower financial leverage with a 0.71x debt-to-equity ratio, signaling a more conservative balance sheet compared to CC's 18.27x. On the Piotroski fundamental quality scale (0–9), CBT scores 6/9 vs TROX's 2/9, reflecting solid financial health.
| Metric | CBTCabot Corporation | TROXTronox Holdings p… | CCThe Chemours Comp… | KROKronos Worldwide,… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | +16.8% | -30.4% | -163.4% | -17.0% |
| ROA (TTM)Return on assets | +7.4% | -7.7% | -5.5% | -9.4% |
| ROICReturn on invested capital | +17.4% | -0.3% | -0.1% | -1.9% |
| ROCEReturn on capital employed | +21.3% | -0.4% | -0.1% | -2.2% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 2 | 4 | 5 |
| Debt / EquityFinancial leverage | 0.71x | 2.48x | 18.27x | 0.77x |
| Net DebtTotal debt minus cash | $957M | $3.4B | $3.9B | $540M |
| Cash & Equiv.Liquid assets | $258M | $211M | $672M | $37M |
| Total DebtShort + long-term debt | $1.2B | $3.6B | $4.6B | $577M |
| Interest CoverageEBIT ÷ Interest expense | 14.72x | -1.16x | 1.15x | -2.32x |
CBT leads this category, winning 7 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
CBT leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CBT five years ago would be worth $14,321 today (with dividends reinvested), compared to $4,493 for TROX. Over the past 12 months, CC leads with a +108.8% total return vs KRO's -1.2%. The 3-year compound annual growth rate (CAGR) favors CBT at 7.0% vs TROX's -8.6% — a key indicator of consistent wealth creation.
| Metric | CBTCabot Corporation | TROXTronox Holdings p… | CCThe Chemours Comp… | KROKronos Worldwide,… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | +21.9% | +98.1% | +83.6% | +58.5% |
| 1-Year ReturnPast 12 months | +13.8% | +76.9% | +108.8% | -1.2% |
| 3-Year ReturnCumulative with dividends | +22.5% | -23.6% | -15.7% | -0.7% |
| 5-Year ReturnCumulative with dividends | +43.2% | -55.1% | -22.7% | -43.9% |
| 10-Year ReturnCumulative with dividends | +115.7% | +116.1% | +219.7% | +129.0% |
| CAGR (3Y)Annualised 3-year return | +7.0% | -8.6% | -5.5% | -0.2% |
CBT leads this category, winning 3 of 6 comparable metrics.
Risk & Volatility
CBT leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
CBT is the less volatile stock with a 0.78 beta — it tends to amplify market swings less than TROX's 2.37 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CBT currently trades 96.1% from its 52-week high vs CC's 78.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CBTCabot Corporation | TROXTronox Holdings p… | CCThe Chemours Comp… | KROKronos Worldwide,… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.78x | 2.37x | 1.92x | 1.57x |
| 52-Week HighHighest price in past year | $84.60 | $10.59 | $28.67 | $7.90 |
| 52-Week LowLowest price in past year | $58.33 | $2.86 | $9.13 | $4.08 |
| % of 52W HighCurrent price vs 52-week peak | +96.1% | +79.4% | +78.1% | +89.2% |
| RSI (14)Momentum oscillator 0–100 | 71.7 | 58.5 | 48.1 | 63.4 |
| Avg Volume (50D)Average daily shares traded | 374K | 3.1M | 3.1M | 350K |
CBT leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Evenly matched — CBT and TROX each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: CBT as "Buy", TROX as "Buy", CC as "Hold", KRO as "Hold". Consensus price targets imply -1.2% upside for CC (target: $22) vs -29.1% for KRO (target: $5). For income investors, TROX offers the higher dividend yield at 3.60% vs CBT's 2.18%.
| Metric | CBTCabot Corporation | TROXTronox Holdings p… | CCThe Chemours Comp… | KROKronos Worldwide,… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Hold | Hold |
| Price TargetConsensus 12-month target | $78.00 | $7.25 | $22.14 | $5.00 |
| # AnalystsCovering analysts | 15 | 17 | 20 | 7 |
| Dividend YieldAnnual dividend ÷ price | +2.2% | +3.6% | +2.3% | +2.8% |
| Dividend StreakConsecutive years of raises | 4 | 0 | 0 | 0 |
| Dividend / ShareAnnual DPS | $1.77 | $0.30 | $0.52 | $0.20 |
| Buyback YieldShare repurchases ÷ mkt cap | +4.0% | 0.0% | 0.0% | 0.0% |
Evenly matched — CBT and TROX each lead in 1 of 2 comparable metrics.
Key Takeaway
CBT leads in 5 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 1 category is tied.
Best OverallCabot Corporation (CBT)Leads 5 of 6 categories
Loading custom metrics...
CBT vs TROX vs CC vs KRO: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is CBT or TROX or CC or KRO a better buy right now?
For growth investors, The Chemours Company (CC) is the stronger pick with 0.
4% revenue growth year-over-year, versus -7. 0% for Cabot Corporation (CBT). Cabot Corporation (CBT) offers the better valuation at 13. 5x trailing P/E (13. 0x forward), making it the more compelling value choice. Analysts rate Cabot Corporation (CBT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — CBT or TROX or CC or KRO?
On forward P/E, Cabot Corporation is actually cheaper at 13.
0x.
03Which is the better long-term investment — CBT or TROX or CC or KRO?
Over the past 5 years, Cabot Corporation (CBT) delivered a total return of +43.
2%, compared to -55. 1% for Tronox Holdings plc (TROX). Over 10 years, the gap is even starker: CC returned +219. 7% versus CBT's +115. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — CBT or TROX or CC or KRO?
By beta (market sensitivity over 5 years), Cabot Corporation (CBT) is the lower-risk stock at 0.
78β versus Tronox Holdings plc's 2. 37β — meaning TROX is approximately 202% more volatile than CBT relative to the S&P 500. On balance sheet safety, Cabot Corporation (CBT) carries a lower debt/equity ratio of 71% versus 18% for The Chemours Company — giving it more financial flexibility in a downturn.
05Which is growing faster — CBT or TROX or CC or KRO?
By revenue growth (latest reported year), The Chemours Company (CC) is pulling ahead at 0.
4% versus -7. 0% for Cabot Corporation (CBT). On earnings-per-share growth, the picture is similar: Cabot Corporation grew EPS -10. 4% year-over-year, compared to -890. 0% for Tronox Holdings plc. Over a 3-year CAGR, KRO leads at -1. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — CBT or TROX or CC or KRO?
Cabot Corporation (CBT) is the more profitable company, earning 8.
9% net margin versus -16. 2% for Tronox Holdings plc — meaning it keeps 8. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CBT leads at 16. 7% versus -1. 7% for KRO. At the gross margin level — before operating expenses — CBT leads at 25. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is CBT or TROX or CC or KRO more undervalued right now?
On forward earnings alone, Cabot Corporation (CBT) trades at 13.
0x forward P/E versus 15. 5x for The Chemours Company — 2. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CC: -1. 2% to $22. 14.
08Which pays a better dividend — CBT or TROX or CC or KRO?
All stocks in this comparison pay dividends.
Tronox Holdings plc (TROX) offers the highest yield at 3. 6%, versus 2. 2% for Cabot Corporation (CBT).
09Is CBT or TROX or CC or KRO better for a retirement portfolio?
For long-horizon retirement investors, Cabot Corporation (CBT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
78), 2. 2% yield, +115. 7% 10Y return). Tronox Holdings plc (TROX) carries a higher beta of 2. 37 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CBT: +115. 7%, TROX: +116. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between CBT and TROX and CC and KRO?
Both stocks operate in the Basic Materials sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: CBT is a small-cap deep-value stock; TROX is a small-cap income-oriented stock; CC is a small-cap quality compounder stock; KRO is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(CBT: -3.4% · TROX: 3.0%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.